<DOC>
	<DOCNO>NCT00003950</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Cyclosporine may relieve diarrhea cause irinotecan . PURPOSE : Phase II trial study effectiveness irinotecan cyclosporine treat patient metastatic , advanced , locally recurrent colorectal cancer respond fluorouracil .</brief_summary>
	<brief_title>Irinotecan Cyclosporine Treating Patients With Metastatic , Advanced Locally Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient metastatic , advanced , locally recurrent fluorouracil refractory adenocarcinoma colon rectum treat irinotecan cyclosporine . II . Determine antitumor activity , safety , tolerance , toxicity combination treatment patient . OUTLINE : This multicenter study . Patients receive cyclosporine IV 6 hour irinotecan IV 90 minute weekly 4 week . Courses repeat every 6 week . Patients receive least 2 course absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 15-45 patient accrue study 14 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic , advanced , locally recurrent fluorouracil ( 5FU ) refractory adenocarcinoma colon rectum Progression disease within 6 month receive adjuvant 5FU base chemotherapy OR Progression disease follow completion 5FU base chemotherapy metastatic disease No 1 failure 5FU regimen recurrent , advance , metastatic disease Failure 5FU adjuvant therapy must accompany failure 5FU therapy metastatic disease Bidimensionally measurable disease CNS metastases allow measurable disease sit Prior treatment CNS metastases require PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3500/mm3 Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST ALT great 3 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : No significant , uncontrolled underlying medical psychiatric condition No serious active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Neurologically stable No prior malignancy within past 5 year except curatively treat nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : See Disease Characteristics Prior adjuvant fluorouracil ( 5FU ) allow No 2 prior 5FU regimen ( 1 recurrent metastatic disease ) No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy ( except contraceptive replacement steroid ) No concurrent IV steroid Radiotherapy : Prior radiotherapy allow measurable disease outside radiation port At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify Other : No concurrent anticonvulsant therapy No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>